National Children's Day: Early detection and insulin access vital for Indonesian children with Type 1 diabetes

Type 1 diabetes in children continues to pose a serious challenge in Indonesia, primarily because it is often diagnosed late. This delay in detection and treatment significantly raises the risk of complications, making early diagnosis, comprehensive education, and accessible healthcare crucial for improving the quality of life for young patients.

In recognition of National Children's Day, Novo Nordisk Indonesia has reaffirmed its commitment to enhancing healthcare services for children with type 1 diabetes. The company is working in collaboration with the Ministry of Health, the Indonesian Pediatric Society (IDAI), and other stakeholders to address this issue. Banarsono Trimandojo, Associate Director of Market Access and Public Affairs at Novo Nordisk Indonesia, emphasized that every child deserves access to proper diagnosis, treatment, and support.

According to the International Diabetes Federation (IDF), approximately one-third of type 1 diabetes patients in Indonesia are children and adolescents. This statistic highlights the urgent need to strengthen the pediatric healthcare system, from initial detection through long-term management. Children with type 1 diabetes require lifelong insulin therapy, regular blood sugar monitoring, and continuous medical support to thrive.

To meet these needs, Novo Nordisk has been implementing the 'Changing Diabetes in Children' (CDiC) program in Indonesia since 2021. This initiative, in partnership with the Ministry of Health and IDAI, focuses on four key areas: educating patients and their families, enhancing the capacity of healthcare professionals, expanding access to diabetes care and insulin, and supporting blood glucose monitoring. The program includes educational sessions, diabetes camps, training for medical staff, and support for specialized clinics, aiming to improve the overall management and outcomes for children living with type 1 diabetes.

“

The future of Indonesia is determined by the quality of health of its young generation. Therefore, we are committed to continuing to synergize with various stakeholders to ensure that every child living with type 1 diabetes receives access to appropriate diagnosis, treatment, and support.